Showing 14 posts of 14 posts found.


Alkermes snaps up Rodin Therapeutics for a potential $950 million

November 19, 2019
Manufacturing and Production, Sales and Marketing Alkermes, Rodin Therapeutics, pharma

Dublin’s Alkermes is set to acquire US firm Rodin Therapeutics in a deal worth a potential $950 million, it has …

FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis

October 30, 2019
Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma

The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …


Biogen & Alkermes’ multiple sclerosis drug proves “statistically superior” to Tecfidera at Phase 3

July 31, 2019
Research and Development Alkermes, Biogen, multiple sclerosis, pharma

Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s …


FDA knocks back Alkermes’ opioid-based depression therapy over lack of evidence

February 4, 2019
Sales and Marketing Alkermes, FDA, major depressive disorder, pharma, rejection

Alkermes experimental opioid-based depression therapy ALKS 5461 has been rejected by the FDA, it has emerged, in the adjunctive treatment …


Committee advises against FDA approval of Alkermes’ novel depression drug

November 2, 2018
Medical Communications, Sales and Marketing Alkermes, FDA, depression, pharma

Alkermes has been knocked back with the disappointing, though not entirely unexpected, news that the FDA-appointed Psychopharmacologic Drugs Advisory Committee …

FDA flip-flops on Alkermes’ drug application

April 17, 2018
Manufacturing and Production, Sales and Marketing Alkermes, FDA, biotech, drugs, pharma, pharmaceutical

Two weeks ago, it looked like the hopes for Alkermes’ ALKS 5461 receiving approval would rely on returning to the …


Alkermes sent reeling as FDA refuses review of depression treatment

April 3, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Alkermes, FDA, depression, major depressive disorder, pharma

Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …

Phase III depression trial success for Alkermes

October 24, 2016
Research and Development, Sales and Marketing ALKS 5461, Alkermes, major depressive disorder

Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …

Alkermes' Richard Pops

Alkermes aims to take the next biotech step

December 3, 2015
Medical Communications, Research and Development Alkermes

“We think we can be the next Biogen, or a Celgene or a Vertex – we have that much firepower …


FDA approves Alkermes schizophrenia treatment

October 6, 2015
Research and Development Alkermes, Aristada, FDA, schizophrenia

The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …


Alkermes schizophrenia drug shines in Phase III

April 8, 2014
Medical Communications, Research and Development, Sales and Marketing Abilify, Alkermes, aripiprazole, schizophrenia

Alkermes’ investigational schizophrenia drug has met its primary endpoint in a pivotal trial, leading the firm to seek regulatory approval …

Alkermes and Elan Drug Technologies complete merger

September 19, 2011
Manufacturing and Production Alkermes, Elan, pharma manufacturing news

The contract manufacturing and development unit of Irish drugmaker Elan has completed a near-$1 billion merger with drug delivery specialist …

Elan manufacturing

Elan sells formulations unit to Alkermes for $960m

May 10, 2011
Manufacturing and Production Alkermes, Elan

Irish drugmaker Elan has finally found a buyer for its Elan Drug Technologies unit, which has been on and off …

Novo Nordisk's Victoza

Novo’s Victoza beats Bydureon in head-to-head trial

March 4, 2011
Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes

Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …

Latest content